| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1716166/0002074003-26-000008.txt","as_of":"2026-04-03T11:12:58.166696+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1716166/0002074003-26-000008.txt","company":"Vivos Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1716166/0002074003-26-000008.txt","article_chars":3530,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_4a59d126ad328eca","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1716166/0002074003-26-000008.txt","content_type":"text/plain","enriched_at":"2026-04-03T13:12:29.487338+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1716166/0002074003-26-000008.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1716166/0002074003-26-000008.txt","source_event_id":"evt_6b1490a090f0","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"e2876cc5ed53dee2","kind":"sec_filing","published_at":"20260402","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-02","2026-03-31"],"entities":[{"asset_class":"equity","name":"Vivos Therapeutics, Inc.","relevance":"issuer","symbol":"VVOS","type":"company"}],"event_type":"listing","information_gaps":["No details on the number of shares converted","No prior known state for comparison"],"key_facts":["Form 4 filed on April 2, 2026","Conversion of $1,400,000 bridge promissory note","Shares converted at $1.09 per share"],"numeric_claims":[{"label":"Amount of bridge promissory note","value":"$1,400,000"},{"label":"Conversion price per share","value":"$1.09"}],"primary_claim":"V-Co Investors 3 LLC converted a $1,400,000 bridge promissory note into shares of Vivos Therapeutics' common stock at $1.09 per share.","relevance_score":0.8,"sentiment":"neutral","source_quality":"high","summary":"Vivos Therapeutics, Inc. filed a Form 4 on April 2, 2026, disclosing the conversion of a bridge promissory note into shares of common stock by V-Co Investors 3 LLC.","topics":["SEC filing","stock conversion","Vivos Therapeutics"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Vivos Therapeutics, Inc. \u00b7 Filed 20260402","ticker":"VVOS","tickers":["VVOS"],"title":"VVOS filed 4","url":"https://www.sec.gov/Archives/edgar/data/1716166/0002074003-26-000008.txt"}... |